Media coverage about TiGenix (NASDAQ:TIG) has trended somewhat positive on Sunday, Accern Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. TiGenix earned a daily sentiment score of 0.13 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 44.7321601829287 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Separately, Zacks Investment Research lowered shares of TiGenix from a “buy” rating to a “hold” rating in a research report on Thursday, January 25th.
TiGenix opened at $41.53 on Friday, Marketbeat reports. TiGenix has a 52 week low of $16.70 and a 52 week high of $48.00. The company has a debt-to-equity ratio of 0.24, a current ratio of 0.71 and a quick ratio of 0.69.
TiGenix NV, a biopharmaceutical company, develops and commercializes therapeutics from its proprietary technology platforms of allogeneic or donor derived stem cells. Its stem cell programs are based on proprietary validated platforms of allogeneic expanded stem cells targeting autoimmune, inflammatory, and heart diseases.
Receive News & Ratings for TiGenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TiGenix and related companies with MarketBeat.com's FREE daily email newsletter.